Alicia Whittlesey is a member of the firm’s Life Sciences Compliance and Regulatory Counseling Department. She focuses her practice on advising clients on the laws and enforcement measures governing the life sciences industry including HIPAA, Anti-Kickback legislation, PhRMA Code, Food, Drug & Cosmetics Act, and FDA guidance and regulations surrounding the compliant advertising and promotion of pharmaceutical products, as well as compliant medical activities.
Ms. Whittlesey has experience analyzing and managing legal and commercial risks from a US and global perspective. With over 15 years of experience working as in-house legal and compliance for multiple companies in the life sciences industry, Ms. Whittlesey leverages her background by providing a valued business perspective guiding teams and stakeholders.
Ms. Whittlesey also works with Porzio Life Sciences, an RLDatix Company. In this capacity, she collaborates with companies to provide regulatory and compliance guidance on programs, policies and procedures that govern the life sciences industry.
"The Intersection of Legal and Compliance – Understanding the Risks of the Federal Anti-Kickback Statute for HCP Engagements & Transparency," 2022 Transparency, Aggregate Spend & HCP Engagement Conference, 8/10/2022
"Closing Remarks," Porzio's Ethics & Eggs 2021, 12/09/2021
"Enforcement Action Current Trends: Compliance Takeaways from the Incyte Complaint," Porzio Life Sciences Webinar, 6/30/2021
"Compliant Patient Interactions," CBI's 16th Annual Pharmaceutical Compliance Congress, 4/18/2019
Prior Relevant Experience
- Biogen, Weston, MA, Commercial Counsel Legal Affairs, 2013-2018
- Sunovion Pharmaceuticals Inc. (formerly sepracor Inc.), Marlborough, MA, Counsel, 2008-2010; Senior Counsel, Commercial Legal Affairs, 2010-2012
- Bristol-Myers Squibb Company, Plainsboro, NJ, Associate Counsel, 2005-2008
- Eisai Inc, Teaneck, NJ, Administrative Assistant, Paralegal, 1996-2002; Counsel, 2002-2005